Apolipoprotein KV domain (67 – 77) – Ion Channels and Transporters

Vascular lipid deposition and altered lipid profiles are typical when unregulated angiogenesis is occurring, it is often seen in vascular disorders such as cancer and atherosclerosis. Apolipoprotein a (ApoA) functions as part of the lipid transporter complex high-density lipoproteins (HDL) to ensure lipid homeostasis and therefore the balance of angiogenesis. Within ApoA the Kringle5 (KV) domain (67 – 77), also known as KV11, has been identified as the region of ApoA that exerts anti-angiogenic effect. KV11 was shown in tumour cells to inhibit angiogenesis and consequently inhibits tumour progression. KV11 targets the angiogenesis c-Src/ERK pathway by blocking the activation signals received from vascular endothelial growth factor (VEGF). KV11 provides a new research potential for an anti-angiogenesis and anti-tumour therapeutic agent.

 

Technical specification

 KD20 peptide Sequence : H-YTMNPRKLFDY-OH
 KD20 peptide MW : 1.447.66 g/mol
 KD20 peptide Purity : > 95%
 KD20 peptide Counter-Ion : TFA Salts
Peptide library synthesis KD20 peptide Delivery format : Lyophilized

Price

 

Product Size Price €
Price $
CRB1000161-0.5 mg 0.5 mg 141 € 113 $
CRB1000161-1 mg 1 mg 193 € 154 $
CRB1000161-
CRB1000161-
CRB1000161-

For Bulk Orders